RAY1225
Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight
Guangdong Raynovent Biotech Co · Phase 3 · Recruiting · Enrollment 640
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| RAY1225 High Dose | n/r | n/r | n/r | n/r |
| RAY1225 Medium Dose | n/r | n/r | n/r | n/r |
| RAY1225 Low Dose | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- RAY1225 High Dose: endpoint not reported
- RAY1225 Medium Dose: endpoint not reported
- RAY1225 Low Dose: endpoint not reported
- Placebo: endpoint not reported